Voyager Acquisition Corp. (VACHU) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 14.5 |
| Open | 14.52 |
| Day High | 14.52 |
| Day Low | 14.5 |
| 52-Week High | 20.1 |
| 52-Week Low | 10.08 |
| Volume | 0 |
| Average Volume | 811 |
| Market Cap | 475.46M |
| PE | 0 |
| EPS | 0 |
| Moving Average 50 Days | 12.71 |
| Moving Average 200 Days | 11.38 |
| Change | 1 |
Data not available
VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies
GlobeNewswire Inc.
Apr 23, 2025 5:00 AM GMT
VERAXA’s Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug Conjugate ("ADC") and Bispecific T-cell Engager ("TCE") Candidates, with Strong and Differentiated Clinica
Voyager Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing on or about September 30, 2024
GlobeNewswire Inc.
Sep 26, 2024 9:33 PM GMT
BROOKLYN, N.Y., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Voyager Acquisition Corp. (Nasdaq: VACHU) (the “Company”) announced that holders of the units sold in the Company’s initial public offering of 25,300,000 units, which includes 3,300,000 units issue